HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES

摘要

The present application describes novel hydantoin derivatives of formula (I), or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R?1, R2, R3, R4, R5, R6, R7, R11¿, and n are defined in the present specification, which are useful as inhibitors of matrix metallproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.